Showing results (171-180 of 187) with videos related to

Sort By:
Pageof 19
Bioscience Reports|April 16, 2021
HDAC6 inhibitor WT161 performs anti-tumor effect on osteosarcoma and synergistically interacts with 5-FUJun Sun, Wei Wu, Xiaofeng Tang, et al.
Frontiers in Immunology|May 15, 2023
Immune desert in MMR-deficient tumors predicts poor responsiveness of immune checkpoint inhibitionGuoxing Zheng, Yingsi Lu, Zheng Yang, et al.
Aging|February 3, 2021
High expression of vinculin predicts poor prognosis and distant metastasis and associates with influencing tumor-associated NK cell infiltration and epithelial-mesenchymal transition in gastric cancerHuafu Li, Chunming Wang, Linxiang Lan, et al.
Alimentary Pharmacology & Therapeutics|June 30, 2020
Regular use of proton pump inhibitor and risk of rheumatoid arthritis in women: a prospective cohort studyJinqiu Yuan, Changhua Zhang, Jeffrey A Sparks, et al.
BMC Medicine|August 23, 2022
Efficacy of SCF drug conjugate targeting c-KIT in gastrointestinal stromal tumorDengyang Zhang, Chunxiao He, Yao Guo, et al.
BMC Medicine|December 3, 2021
Regular use of proton-pump inhibitors and risk of stroke: a population-based cohort study and meta-analysis of randomized-controlled trialsMan Yang, Qiangsheng He, Fang Gao, et al.
Molecular Cancer|June 7, 2024
OLFM4 promotes the progression of intestinal metaplasia through activation of the MYH9/GSK3β/β-catenin pathwayHongfa Wei, Wenchao Li, Leli Zeng, et al.
Ebiomedicine|March 13, 2021
An integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancerZhijun Zhou, Junxia Zhang, Chao Xu, et al.
International Journal of Cancer|May 21, 2021
Association of body composition with risk of overall and site-specific cancers: A population-based prospective cohort studyQiangsheng He, Bin Xia, Anran Liu, et al.
Nature|July 3, 2024
NBS1 lactylation is required for efficient DNA repair and chemotherapy resistanceHengxing Chen, Yun Li, Huafu Li, et al.
Pageof 19